975 results on '"Abildgaard Niels"'
Search Results
2. Relationship between reasons for intermittent missing patient-reported outcomes data and missing data mechanisms
3. In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease
4. Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic Myeloma Study Group
5. Intensifying treatment in PET-positive multiple myeloma patients after upfront autologous stem cell transplantation
6. Potential value of pre-planned imaging of bone disease in multiple myeloma
7. Real-world treatment patterns and outcomes for patients with multiple myeloma in Denmark, Finland and Sweden: An analysis using linked Nordic registries
8. The coverage of influenza vaccination and predictors of influenza non-vaccination in Danish cancer patients: A nationwide register-based cohort study
9. No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma
10. Reproducibility of low-level residual myeloma immunoglobulin detection using ultra-deep sequencing
11. Comparative evaluation of the heterozygous variant standard deviation as a quality measure for next-generation sequencing
12. A polygenic risk score for multiple myeloma risk prediction
13. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial
14. Exercise in newly diagnosed patients with multiple myeloma: A randomized controlled trial of effects on physical function, physical activity, lean body mass, bone mineral density, pain, and quality of life.
15. Limited Evidence for the Benefits of Exercise in Older Adults with Hematological Malignancies: A Systematic Review and Meta-Analysis.
16. STAT3 is over-activated within CD163pos bone marrow macrophages in both Multiple Myeloma and the benign pre-condition MGUS
17. Assessment of atherosclerosis in multiple myeloma and smoldering myeloma patients using 18F- sodium fluoride PET/CT
18. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
19. Strategies to improve patient-reported outcome completion rates in longitudinal studies
20. Perspective: sensitive detection of residual lymphoproliferative disease by NGS and clonal rearrangements—how low can you go?
21. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group
22. Use of bisphosphonates in multiple myeloma patients in Denmark, 2005–2015
23. Molecular characterization of sorted malignant B cells from patients clinically identified with mantle cell lymphoma
24. Treatment of the elderly patient with haematological cancer
25. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
26. Detailed characterization of the transcriptome of single B cells in mantle cell lymphoma suggesting a potential use for SOX4
27. Comparison of 18F-sodium fluoride uptake in the whole bone, pelvis, and femoral neck of multiple myeloma patients before and after high-dose therapy and conventional-dose chemotherapy
28. Author Correction: Germline variants at SOHLH2 influence multiple myeloma risk
29. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
30. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
31. Novel Developments in the Treatment of Multiple Myeloma-Associated Bone Disease
32. The potential of 3rd‐generation nanopore sequencing for B‐cell clonotyping in lymphoproliferative disorders
33. Toward Cytogenomics
34. OA-10 Four years treatment with zoledronic acid is superior to two years in protection against progressive bone disease in multiple myeloma
35. P-277 Venetoclax versus bortezomib, in combination with daratumumab and dexamethasone, in patients with t(11;14)-positive relapsed or refractory multiple myeloma
36. Use of Linked Nordic Registries for Population Studies in Hematologic Cancers: The Case of Multiple Myeloma
37. Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study
38. Genetically determined telomere length and multiple myeloma risk and outcome
39. Germline variants at SOHLH2 influence multiple myeloma risk
40. Incidence and clinical characteristics of multiple myeloma with low M-protein levels and normal values of hemoglobin, creatinine, calcium, and serum free light chain ratio
41. Effects of live music during chemotherapy in lymphoma patients: a randomized, controlled, multi-center trial
42. The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials
43. Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13
44. PB2394: PTPRJ AS A ROBUST DIFFERENTIATING MARKER IN MANTLE CELL LYMPHOMA
45. P919: TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WITH ZOLEDRONIC ACID FOR FOUR YEARS INSTEAD OF TWO YEARS DECREASES RISK OF PROGRESSIVE BONE DISEASE WITHOUT INCREASING RISK OF OSTEONECROSIS OF THE JAW.
46. PB2386: ASSESSMENT OF NANOPORE LONG-READ WHOLE-GENOME SEQUENCING FOR THE DETECTION OF LARGE CHROMOSOMAL STRUCTURAL VARIANTS IN MANTLE CELL LYMPHOMA
47. P1671: CARFILZOMIB-DEXAMETHASONE MAINTENANCE HAMPERS RECOVERY AFTER SALVAGE AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
48. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group
49. Physical function in patients newly diagnosed with multiple myeloma; a Danish cohort study
50. The potential of 3rd‐generation nanopore sequencing for B‐cell clonotyping in lymphoproliferative disorders.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.